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Abstract: In this paper, we document the lessons from the development of chemical biology platform in 
a major pharmaceutical company, and the outcomes of the early phases of this experiment. Although the 
concept of chemical biology is not new, its evolution and deployment in the drug development process is 
relatively new. The present experiment thus has to deal with both the scientific novelty of chemical biology, 
and organizational challenge of embedding it in the ongoing process of drug development. The notion of 
virtual communities or platforms overlaid on the traditional matrix of drug development served to introduce 
the approach, with some remarkable outcomes. 
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 Introduction 
In spite of widely heralded breakthroughs such 
as the human genome project, the innovation 
performance of the pharmaceutical industry as a 
whole has been lackluster. Although the specific 
figures are often under dispute, there is general 
agreement that the increasing costs of R&D1 
coupled with a stagnating number of chemical 
entities reaching the market often are interpreted 
to be signals of declining innovation performance 
in the industry as a whole. This 'innovation deficit' 
is not due to the lack of diseases needing remedies, 
or of drug targets, upon which drugs can be 
designed (1). Rather, it is attributable to the 
process of drug innovation or the means by which 
targets are brought into the market.  
No doubt recent years have witnessed 
remarkable innovations in the process of drug 
discovery and development. Advanced 
technological innovations have made it possible to 
do the screening of compounds for chemical 
properties at a high rate. But these innovations 
have not resulted in innovation efficiencies 
expected by their proponents; they have simply 
sped up our ability to screen compounds. The 
failures of these innovations call for rethinking the 
approach to the problem. 
In this paper, we summarize a case study of the 
introduction of chemical biology (CB) platform to 
speed up the process and enhance the 
effectiveness of the drug discovery process in a 
major pharmaceutical company. CB platform 
deploys emerging ideas from knowledge 
management to distill lessons from past 
experiences in drug development; but unlike many 
KM approaches, CB approach opens up new 
scientific frontiers at the junctures of chemistry 
and biology, relevant to drug innovation.  
The scheme of this paper is as follows. In the 
first section, we outline our view of KM as 
practiced in organizations. Our intent is not to be 
exhaustive in our treatment of KM, but highlight a 
                                               
1 The December 2001 estimates by the Tufts center suggest 
that the R&D costs for a new prescription drug have risen 
to slightly over 800 million dollars, due to rising clinical 
trial costs, expanding development programs, more 
chronic and degenerated diseases, and longer development 
times.   
few ideas to anchor our discussion of the 
development of CB platform. In the second 
section, we articulate the concept of CB to 
highlight the scientific novelty of this emerging 
field, as well as the unique features of this platform 
that set it apart from other KM exercises. Thus 
our treatment here is not to highlight the scientific 
aspects of this field, but the excitement, 
uncertainties and risks associated with its 
introduction.  In the third section, we summarize 
the industry and organizational contexts that 
prompted the introduction of CB platform. In the 
fourth section, we discuss the introduction and 
preliminary outcomes of introduction of CB 
platform. Finally, we highlight the major lessons 
from the experiment.  
 
I. Knowledge Management 
Approaches: An Overview  
Knowledge Management (KM) emerged over 
the past five years or so as a significant 
management discipline with its own body of 
concepts, language, and practices (2).  Broadly 
conceived, KM enables, supports, and encourages 
the following three interrelated foci:  
 
1. The processes of discovering or creating new 
knowledge and refining existing knowledge; 
 
2. The sharing of knowledge among individuals, 
and across all organizational boundaries; and, 
 
3. The continued development and use of 
knowledge as part of individuals’ day-to-day 
work, and as part of decision-making.  
   
But knowledge is not managed for its own sake.  
Rather the intent is to contribute to superior 
organizational performance (3), internal operating 
proficiency (4), and the quality-of-life of 
organizational members. 
The evolving understanding of knowledge in 
organizational settings unavoidably brings in its 
wake two central knowledge challenges: (1) how to 
bring individuals together to create, share, and 
leverage knowledge, and (2) how to do so most 
efficiently and effectively in the interests of 
achieving the goals outlined above.   
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Two broad approaches to managing the 
knowledge challenges appear to dominate both the 
literature and practice in organizations: 
Organizations deploy human and organizational 
arrangements to practice KM; they also deploy 
information technologies to contribute to 
knowledge work.  The organizational and IT 
approaches have been applied to both intra-
organizational and inter-organizational locales 
(exchanges within and across the organization’s 
boundaries respectively).  These two locales 
involve different contextual features that influence 
the content, direction, and intent of KM.  For 
example, knowledge sharing-- a central focus in 
much of intra organizational approaches-- is 
influenced by the threat of intellectual property 
loss when applied to exchanges across the 
boundaries.  
 
The organizational approach to KM explicitly 
addresses the human side of knowledge.  It 
involves managing four interrelated elements so that 
individuals and  groups better generate, share and 
leverage knowledge:  1) The choice, adoption and 
implementation of procedures or methods to bring 
individuals and groups together (who otherwise 
might not do so); 2) The formal and informal 
organizational settings in which individuals 
interact; 3) The organizational routines (e.g., 
process reviews, business case development) in 
which work occurs; and, 4) the organizational 
context in which all interactions and work take 
place, for example, creating and sustaining a 
knowledge-friendly culture (5,6,7).  
 
The technological approach to KM involves the 
choice, adoption and implementation of 
information and related technologies.   It requires 
the management of at least three distinct but 
related elements: 1) technologies that enable data 
gathering, massaging, mining and other data 
integration tools: these tools often involve 
establishing and refining many forms of data bases 
and/or automating, reconfiguring or integrating 
organization routines, processes or “best 
practices”; 2) technologies that enable data and 
information dissemination, distribution and 
deployment often requiring and enabling direct 
organization-wide or select involvement by 
individuals and groups; and 3) technologies that 
enable direct and real-time interactions among and 
between individuals and groups, often in distant 
geographical quarters, so that they can converse 
with each other, share data and information, as 
well as offer opinions, judgments and critique 
(8,9).  Its overarching intent is to enable the timely 
provision of more and higher quality data and 
information, both selectively and generally, to 
individuals and groups throughout the 
organization.   
  
The technological approaches dominated the 
early stages of KM, and were useful in 
understanding the patterns within explicit 
knowledge as captured by electronic data bases. 
However these approaches could not migrate to 
scientific disciplines within organizations. Recently 
organizational approaches (e.g., communities of 
practice or COP’s) have been introduced as KM 
mechanism in scientific circles. However, in most 
of the current practice, these approaches were a 
means of transferring tacit knowledge from 
scientist to scientist. Several characteristics of 
chemical biology approach pose unique challenges 
to KM, a topic to which we now turn.  
II. Chemical Biology 
Two intertwined characteristics of CB set it apart 
from current KM applications. First, it is an 
interdisciplinary field that necessitates 
collaborations across disciplines; second, at 
present, it is in an embryonic stage that creates 
significant uncertainty about its definition, content 
and potential. We will take up each before we 
discuss their implications for drug development.  
Interdisciplinary field 
Historically, chemistry was primarily focused on 
structure and synthesis, and biology with function. 
Research into structure-function relationships 
remained an undeveloped interdisciplinary topic. 
In drug discovery both disciplines are important. 
As articulated by Wess, Urmann, & Sickenberger 
(2001), chemistry is necessary for the identification 
of new lead compounds, their optimization to 
clinical candidates, and for the provision of 
sufficient amounts of these substances for further 
studies and for development or scaling up.  
Biology's need is transparent: After all, drug 
discovery is for treating biological malfunctions in 
the human body. 
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Over the years, the dialogue between chemists 
and biologists have been deepening, partly 
stimulated by the pressures of the pharmaceutical 
industry. Yet the chasm between the two 
remained, and many of the interdisciplinary 
aspects of the relationship between the two 
remained undeveloped. Recently, decoding the 
human genome has led to the estimate that out of 
more than 30,000 human genes, at least 1,000 are 
significantly involved in the emergence and course 
of disease (11). In turn, this has led to the 
conclusion that there might be 5000 to 10,000 
genes that are targets for new drugs. These 
conclusions imply that the race is intensifying in 
the pharmaceutical industry as to who can develop 
the targets into commercially viable drugs. 
Furthermore, given these advances in biology, 
chemists now have a strong incentive to evolve 
their field as to remain relevant in today's research 
context.  
One approach to sketching the structure -
function relationships is chemical biology (CB). 
'Chemical biology' is a term arguably first 
advanced by Schreiber and Nicolau in a series of 
papers (12, 13). In a broad sense, CB aims to 
create biological response profiles by small 
molecules, selected on the basis of our state of 
knowledge about the structures and functions of 
biological targets. To accomplish this, however, 
biologists and chemists have to jointly generate 
knowledge about the structure and function of 
biological targets, and turn this knowledge into  
 
 
new molecules and then create relevant biological 
responses.  Although the field is beginning to be 
established in the academia, it had not been 
implemented in the pharmaceutical industry.   
Embryonic Field 
Given the relatively recent emergence of CB, the 
scientific uncertainty surrounding the efficacy of 
this approach is unknown or at best uncertain. At 
this stage of development, CB promises rich 
dividends by concentrating research into structural 
and functional relationships. Patent remedies to 
address this problem are not yet available in the 
pharmaceutical industry. Rules need to be found 
for the design of profiles and a technology-
integrated and information-based approach that 
transcends the synthetic skills and particular 
preferences of the chemists or the historic areas of 
activity of the firms needs to be followed.  
The embryonic nature of the field is reflected in 
another set of circumstances. Currently, there are 
no individuals who are professionally trained and 
certified as chemical biologists; there are few 
universities which offer programs in this field. 
Thus for aspiring scientists, there are few role 
models of success: They will have to innovate and 
chart their own paths as they participate in the 
development of the field.  
 
 
 
 
 
Traditional 
 
 
Chemical Biology 
Ø Trail and error, high throughput technologies Ø Focus on selected target families and systems 
biology approaches 
 
Ø Limited success rates for new biological targets Ø Accumulation of knowledge on chemical and 
biological structure spaces, learning curves 
 
Ø Separate functional disciplines Ø Interdisciplinary problem solving 
 
Ø Sequential processes in biology and chemistry Ø Parallel processes 
 
Ø Low degree of specialization in chemistry Ø Specialists in chemistry, new skill sets 
 
 Ø Networks of knowledge, partnering 
 
 
Table 1: „Traditional“ versus „Chemical Biology“ (adapted from Wess [10]). 
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Implications for drug development 
CB implies a radically different process of drug 
discovery. This approach was first articulated by 
Douglas in his 2000 keynote address at the Drug 
Discovery and Technology conference (14).  See 
Table 1 for these differences. Especially in lead 
generation, the existing approach relies on trial and 
error method combined with high throughput 
technologies, sequential orientation and 
dominance of functional silos. CB requires a focus 
on targeted families and system biology 
approaches, interdisciplinary problem solving and 
parallel, information-driven and technology 
approaches.  
 
These differences have two major implications: 
1. Since CB involves reorienting the process of 
drug discovery, any drug discovery and 
development organization that wants to 
institute CB will have to undertake a significant 
organizational change effort. 
2. CB requires building up scientific knowledge, a 
process that can benefit from knowledge 
management (KM) approaches being instituted 
in organizations.  Although KM has to date 
been employed in operations and management 
decision making, CB requires adaptation of 
these approaches to deal with the uncertainties 
of this embryonic field.  
III. Industry and Organizational 
Context 
Industry context 
The pharmaceutical industry of the 21st century 
faces unparalleled challenges. Rising clinical trial 
costs due to difficulty in recruiting patients, 
expanding development programs, more chronic 
and degenerated diseases and longer development 
times have led to a condition where the innovation 
productivity of the industry – new medical entities 
relative to the dollar invested has declined. This 
perceived lack of productivity is worsened by the 
industry-wide realization we underscored above, 
brought home by the recent successes of the 
human genome project -- that there are finite 
targets which all firms will be interested in their 
attempts to find cures for various diseases. These 
conditions, together with increasing societal 
expectations are putting pressure on 
pharmaceutical firms simultaneously to speed up 
and increase the effectiveness of the drug 
development process.  
Various organizations have responded 
differently to these threats. But the organizational 
contexts of pharmaceutical firms display 
similarities.   
Organizational context 
As in a typical pharmaceutical firm, project 
teams are the units of innovation in Aventis. 
Various projects are managed by cross-functional 
teams. However, at Aventis, the Research and 
Development organization is made up of a matrix 
of globally coordinated as well as site specific 
functions. For example, chemistry, functional 
genomics, toxicology, clinical pharmacology are 
globally coordinated functions with units at each 
of the three major Discovery sites. Each discovery 
site has groups of Biologists (molecular biologists, 
biochemists, pharmacologists) that specialize in 
specific disease or therapeutic areas and form the 
core of the early stage cross functional teams. The 
role of the functions, be they globally coordinated 
or site-specific, is to supply the best people 
(knowledge) and technological solutions to address 
the specific challenges of the project team.  These 
project teams drive drug discovery and 
development, with leaders expected to make 
decisions.  
These teams operate in the Drug Innovation & 
Approval (DI & A) group within Aventis. DI&A 
is organized into functions and disease groups: 
Global functions cut across therapeutics areas, 
whereas therapeutic areas confined to a single site. 
Thus, individuals operate in a matrix, function or 
therapeutic area and project teams. Aventis 
renamed its R&D organization: Drug Innovation 
and Approval (DI&A) to emphasize the 
importance of its scientists focusing their activities 
on discovering innovative drugs and getting them 
approved. Unique to Aventis, DI&A organization 
is the Lead Optimization (LO) organization, 
consisting of the globally coordinated disciplines 
of Pharmacokinetics, Toxicology, Clinical Phase 1 
and 11A. Lead Optimization bridges Discovery 
and late stage clinical Development, Phase11B and 
111. The disciplines in LO support the project 
      Journal of Business Chemistry  Narayanan, Douglas, Schirlin, Wess, Geising September 2004 
 
 
© 2004 Institute of Business Administration                               42      ISSN 1613 – 9615  
 
 www.businesschemistry.org 
team in early testing whether a compound 
demonstrates the biochemical proof of concept 
and finally the clinical proof of concept, before the 
company commits the significant resources that 
are needed in late stage, Phase 11 and Phase 111 
development.    
In the past, Aventis scientists were project-
focused: they did a project and moved on to the 
next. As a result there was no cross-project 
transfer of learning. Functions enable knowledge 
capture and transfer, but their focus is naturally 
functional excellence, albeit global. Site-specific 
disease groups similarly limit knowledge capture 
and deployment to their respective disease groups. 
The limited cross project transfer of knowledge led 
to a context where ‘targets’, the focus of CB, were 
typically not tracked.  
IV. Introduction of CB Platforms in 
Drug Development 
Early discussions 
CB at Aventis was the first implementation in 
large pharma, and it did not happen overnight. 
Over a period of three to four years, prior to the 
introduction of CB platform, discussions among 
very senior R&D managers focused on the gaps in 
the then prevalent drug discovery approaches. By 
2000, this group had arrived at the conclusion that 
the links between structural biology and chemistry 
remained a major gap, and the trial and error 
approach can be improved by the deepening the 
knowledge of ‘chemical biology.’ This conclusion 
was imbued with a sense of urgency when it 
became clear that Craig Venter and others had 
arrived at an incredible breakthrough in the human 
genome project. Douglas in one of two keynote 
addresses at the 2000 Drug Discovery Forum & 
Technology forum in Boston decided to commit 
Aventis to the application of chemical biology, as 
one way to take advantage of the potential classes 
of targets that were implied in the other keynote 
address that was presented by Craig Venter.  
Management strategy 
After the initial decision to commit to CB 
approach, the task of crafting a management 
strategy to implement this approach began. 
Although the senior leaders had a clear conception 
of what CB should do, the rank and file scientists 
who would actually be developing the scientific 
concepts, models and methods of CB were not 
privileged to be part of these early deliberations. 
An initial decision was to appoint a leader for the 
initiative. The chosen leader of the CB initiative 
was a long-term insider, a well respected scientist, 
with global experience, and strong interest in 
philosophy and innovation.  
A first approach to sparking the interest of the 
scientists met with mixed results. A kick off 
meeting on CB with 25 promising Aventis 
scientists was held in Germany with the help of 
two McKenzie consultants in the fall of 2000. 
There was no real excitement and a lot of 
skepticism: Unlike the senior managers, they did 
not see much value in the new approach. The 
leader of the CB initiative initially considered the 
meeting to be a disaster: It was “scary” to hear 
such skepticism from young scientists.  
Out of these early experiences, deliberations and 
other concurrent initiatives being implemented in 
the Aventis organization emerged a management 
strategy that was built upon three major anchors: 
(1) Incremental or pilot approach; (2) Project 
focused science; (3) The concept of virtual 
platform. 
1. Incremental approach 
This approach was a direct outgrowth of the 
experiences with other organizational changes that 
Douglas had introduced in some of the Aventis 
predecessor companies.. The skepticism of 
scientists convinced the senior R&D managers 
that rather than adopting an organization-wide 
approach, it may be necessary to adopt a slower, 
incremental approach to introduce and build the 
CB initiative on a pilot basis The pilot approach 
involved starting with a small group of scientists 
focused on a specific set of projects, and over time 
following up with several other projects. It was 
easier to locate a small number of enthusiastic 
scientists within the corporation, and their 
successes, both scientific and organizational, 
would ensure the interest of others.  
 
Over the period of two years, Aventis launched 
four CB platforms: 1) Kinase, 2) G Protein 
Coupled Receptors (GPCRs), 3) Protease and 4) 
Ion channels and transporters.  
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2. Project-focused science 
As we saw in the conception of CB, the 
scientific challenges involved were interdisciplinary 
lying in the intersection of chemistry and biology; 
thus, CB involved scientific work requiring 
removal of the basic/applied science divide. The 
focus was on rapid learning and knowledge 
development, through leveraging results of 
experiments on specific members of a class to 
determine applicability or reason for differences in 
results with other members in the class. Such 
knowledge should improve the predictability of 
finding good lead compounds for members of the 
target family (Kinase, GPCRs, Protease, or Ion 
channel and Transporter). The senior managers 
chose to focus this CB approach on the support of 
the work of ongoing project teams to ensure that 
‘better compounds, faster’ are produced. This 
approach involved keeping the effectiveness of 
drug development at the center stage, and 
developing CB initiative as a means to enhance the 
business objective.  
During the early stages, covered by the study, the 
CB platforms initiated focused on the 
performance of lead (compound) discovery and 
generation, the earlier stages of drug development. 
The expectation was that CB platforms should be 
able to demonstrate results in the short run with 
respect to the speed and efficacy of lead 
generation. The choices of the platform were 
guided by the extent to which they were likely to 
facilitate drug discovery. Indeed all the four 
platforms accounted for over 60 % of compounds 
produced within the company in the 4 years 
following their introduction. The initiatives that 
fell outside of Aventis’s main projects were not 
covered by this approach.  
 
3. The concept of a virtual platform 
As we noted earlier, like most pharmaceutical 
companies, Aventis R&D organization is a matrix: 
scientists belong to a function and to a disease 
group and to a project team. In this structure, 
functional excellence and knowledge of the disease 
are systematically brought to bear upon the drug 
discovery and development decisions. However, 
the knowledge of the target classes is ad hoc, and 
judgmental. Indeed, as we have noted earlier, the 
promise of CB is to infuse the drug discovery and 
development with the knowledge of the target 
classes, so that the process can be sped up and 
made more productive. This means a third 
dimension, over and above function or disease 
group and project, should be added to the 
prevailing matrix.  
For the organizational form, Aventis settled 
upon the concept of virtual platform, an idea 
borrowed from the notion of communities of 
practices (COP) in Knowledge Management (KM). 
A virtual platform is a ‘collateral organization,’ 
made up of scientists with significant experience, 
working parallel to the existing drug discovery and 
development matrix.  Several key characteristics of 
this virtual platform may be enumerated: 
 
· Catalytic function: The function of a virtual 
platform is to influence through knowledge the 
discovery and development process. Since CB 
focuses on the linkage between structural 
biology and chemistry, it enables more rational 
decisions. A virtual platform is expected to 
infuse the project teams with knowledge about 
the targets pertinent to the challenges they are 
facing. This may result in speeding up of 
discovery or early termination of potentially 
infeasible compounds and targets.  
 
· Target focused basic research: A CB platform is 
expected to create new insights regarding the 
linkages between chemistry and biology. This 
may involve distilling the experience of various 
projects regarding particular target classes, both 
within and outside the company to draw 
generalizations, including computer based 
modeling. Indeed, this research provides the 
necessary knowledge base to carry out the 
catalytic function. 
 
· Internal organization: A virtual platform has a clear 
internal organizational structure. It has 1) a 
platform leader, and a core team consisting of 
several members, 2) a sponsor, who is a member 
of the senior management team that supports 
the leader and the core team, 3) several strategy 
groups, each led by a core team member 
working on specific scientific or science-related 
challenges, populated with individuals drawn 
from R&D organization as when and necessary. 
Each platform has significant operational autonomy,  
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Characteristics 
 
 
Platform #1 
 
Platform #2 
 
Platform #3 
 
Platform #4 
Focus Kinase GPCRs Protease Ion Channels & 
Transporters 
Scientific 
Complexity 
Relatively low 
heterogeneity 
  Relatively high 
heterogeneity 
Projects Difficult projects More difficult 
Ease of data 
access 
High Lack of availability 
of global view 
 Acquisition of 
external data 
Extent of in-house 
knowledge 
 
High   Internal & 
External 
Knowledge of CB Low   Increasing 
Availability of 
libraries 
 
Large   
 
Much lower 
 
 
 
 
although all the platforms are encouraged to 
learn from one another. Thus, a virtual platform 
is not a team, but an organization with at least 
four levels. In theory, it interfaces with the 
project teams as and when necessary.  
 
There are significant similarities between the 
virtual platform approach and prevalent KM 
approaches. The virtual platform is about 
knowledge capture and deployment; it uses IT to 
its advantage for both its operations (use of 
website) and codification of knowledge (e.g., 
creation of libraries and data bases); it resembles 
COP’s. There are important differences as well. 
First, the virtual platform concept focuses on 
generating new knowledge, not merely knowledge 
capture. Second, being project-focused, it cuts the 
delay between knowledge capture and deployment. 
Third, a virtual platform is significantly larger in 
size, sometimes resembling a small bio-tech firm.  
Implementation 
Over two years, Aventis implemented four 
platforms: Kinase, GPCR, protease and ion 
channels and transporters. As noted earlier, they 
were chosen for their potential contribution to the 
business purpose. For example, Kinase was chosen 
as the platform given its significance for two very 
important disease groups: oncology and  
 
immunology, and also due to the fact there was a 
large in house library of compounds making it an 
easy ‘demonstration project.’  
A comparative summary of the scientific 
characteristics of the four platforms is presented in 
Table 2. As shown in the table, the four platforms 
were oriented to different disease groups, and had 
different degrees of in house expertise to rely on. 
They were markedly different in terms of the key 
scientific challenges for several reasons: 
 
· The targets themselves were different. For 
example, Kinase, unlike ion channels and 
transporters, represented a relatively 
homogenous group. 
 
· The drug discovery projects addressed by the 
platforms differed in complexity.   
 
· Internally, the accessibility of the data posed 
differing challenges to different platforms.  
 
Indeed these differences imply that the activities of 
various platforms would differ significantly. 
Similarly, a comparative analysis of the organi-
zational characteristics of the four platforms is 
presented in Table 3. The table underscores 
several highlights: 
 
Table 2: Scientific Characteristics of the Four Platforms. 
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Characteristics 
 
 
Platform #1 
 
Platform #2 
 
Platform #3 
 
Platform #4 
Focus Kinase GPCRs Protease Ion Channels & 
Transporters 
Temporal order First Second Third Fourth 
Process consulting 
assistance 
 
External 
 
External 
 
Internal 
 
Internal 
Internal 
organization 
structure 
Platform leader 
Core team 
 
Strategy teams 
Platform leader 
Core team 
 
Strategy teams 
Platform leader 
Core team 
 
Strategy teams 
Platform leader 
Core team 
(7-8 members) 
Strategy teams 
(5 to date) 
Total number of 
people 
 
> 300 
 
Nearly 300 
 
100 – 120  
 
50 – 60 
 
 
 
 
· There was a standard template for almost all 
the internal organization characteristics of the 
platforms. Of course, the platforms differed in 
their total size.  
 
· The tasks confronting each platform and the 
adopted mode of operations differed from one 
another in significant ways. This reflected the 
differences in scientific challenges enumerated 
above.  
 
· There was an attempt to learn from the earlier 
platforms. For example, in later platforms, 
internal consulting replaced external 
consulting. This was facilitated by a ‘Book of 
Knowledge ‘that captured experiences, 
problems and solutions as the Kinase and also 
later platforms were established. Similarly, later 
platforms, by intention, adopted a planned 
approach, unlike the earliest one, Kinase.  
 
· Over time, interface with the project teams 
became stronger. The Kinase group members 
were reluctant to inject their knowledge into 
the working of project teams; this reluctance 
decreased over time, and was much less in ion 
channels and transporters.  
 
· Technology alliances were common, which 
spanned the spectrum from setting up 
 
 
scientific advisory boards, to purchase of data 
bases, outsourcing of some activities.  
 
Indeed, one of the difficulties of assessing the 
accomplishments of a virtual platform, or for that 
matter any catalyst, is due to the fact that a 
platform’s influence is indirect, i.e., through the 
effectiveness of project teams’ decisions. 
Nevertheless, there is reason to believe that the 
platforms yielded a significant return on 
investment.  
V. Key Lessons Learned 
The introduction of CB platform in Aventis 
represented a two-dimensional revolution in the 
way a pharmaceutical company conducted its drug 
discovery process.  On the one hand, it 
represented a scientific revolution, opening up an 
interdisciplinary field, Chemical Biology, hitherto a 
neglected approach to natural sciences. No doubt 
this revolution was made necessary by the failure 
of technology based approaches to drug discovery 
to deliver; it was also made necessary due to the 
competitive pressures triggered by the success of 
human genome project. On the other hand, it 
required a major organizational change within 
Aventis to accommodate the use of knowledge to 
enhance the effectiveness of drug discovery. 
Although any verdict on the long term 
Table 3: Organizational Characteristics of the Four Platforms. 
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effectiveness of CB platform will have to wait until 
the affected drugs are commercialized, the 
preliminary success of this approach emboldens us 
to suggest three key lessons from this experience: 
1) strategic direction of a revolution; 2) Dynamic 
of management; and 3) Challenges of 
accountability. 
 
1. Strategic direction of a revolution: Revolution often 
does not occur in one leap. It sometimes 
comes through a series of baby steps. At the 
same time, the failure of the giant leaps may 
also serve as a prompt to rethink the approach 
to managing a revolution. Revolution involves 
both failures and successes. It is the management 
of failures or rather, framing them as occasions 
of learning that determines how quickly the 
revolution will spread. Finally, it requires in the 
beginning, a small band of committed 
individuals who are willing to share their 
experience, both successes and failures. 
Establishment of a living ‘Book of Knowledge 
‘helps in the sharing of experiences. The key to 
managerial success is to be able to identify 
them early on and nurture them. 
 
2. Dynamic of management: Top down direction was 
essential. The direction took the form of the 
design of organizational mechanisms, not 
scientific approaches. Indeed the dynamic of 
management is essential: specifying the 
overarching goal, finding people, resources, 
and time in a matrixed organization, when 
most of these are not under the control of 
platform leaders. 
 
3. The challenges of accountability: Work approaches 
to various tasks differed across platforms, and 
their outputs were not standardizable. Also, 
measuring the effectiveness of catalytic 
function is tricky. We focused on examples not 
quantitative data. Thus, managers will not be 
able to hide behind numbers when forced to 
defend their decisions. At the same time, 
signaling to external scientific and financial 
communities is necessary to demonstrate the 
sense of accountability. Above all the 
contribution of the platforms was enhanced by 
having shared and aligned objectives between 
the core members of the platforms and the 
heads of functions, whose members were 
supporting project teams of relevance to the 
particular platform. 
 
The approach to building the CB platform 
employed the concept of virtual platform, akin to 
the communities of practice which have 
dominated the organizational approach to KM. 
The virtual platform concept employed 
communities of scientists to examine the 
knowledge base; in that it was similar to COP’s. 
However, the virtual platform differed from 
COP’s prevalent in KM practice in several ways. 
First, the platform was built to create knowledge 
from an interdisciplinary group of scientists; 
second, there was relatively tight linkage between 
knowledge acquisition and utilization, and 
consequently more tangible results; by the 
utilization of technology ( including computer 
modeling), virtual platform interfaced 
organizational and technological approaches in 
KM. In this way, virtual platforms were an 
improvement over the COP’s. However, we do 
not know conditions under which COP’s and 
virtual platforms can be successfully introduced in 
organizations; this remains a major research 
opportunity for the future.  
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